Hansen raises $39m in share sale:
This article was originally published in Clinica
Executive Summary
Robotic catheter control company Hansen Medical is looking to receive approximately $39.4m through a stock offering of three million of its shares. The Mountain View, California-based company will offer the shares at a variable price - the company's estimate for net proceeds from the offering assumes its share price at the end of trading on the Nasdaq Stock Exchange on April 1, which was $14.58 per share. The company intends to spend the proceeds on supporting its sales, marketing and general administrative efforts. Funds will also be used to sustain R&D and for the possible acquisition of new products, technology or complementary businesses. Hansen also said that it expects the proceeds to be used for short- and intermediate-term obligations, depending on the extent of its R&D activities and the amount of cash used by its current operations. The closing date for the offering is April 7.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.